Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

 
You are here: Home / Sites / Duke University Medical Center / Marks, Jeffrey

Marks, Jeffrey (Ph.D.)

PI, Duke University Medical Center, (919) 684-6133

Contact Information

Email: mailto:jeffrey.marks@duke.edu
Fax: (919) 681-6291
EDRN Principal Investigator
Molecular Biology

To update contact information, please visit the Data Management and Coordinating Center.

Open Protocols

Protocol Name Biomarkers Datasets
BBD Reference Set Application: Jeffery Marks-Duke (2015) 0 0
Detection of Serum Markers of Breast Cancer by SELDI 0 0
Expression based markers for breast cancer detection 0 1
Benign Breast Disease Team Project 0 0
DCIS Team Project 0 0
Development of FISH-based assay for early detection of high grade cervical dysplasia 0 0
Early Detection of Breast Cancer Using Autoantibody Markers 0 0
Identification of biomarkers for ER+ breast cancer 0 0
The Early Detection Research Network: Biomarker Reference Laboratories 0 0
Validation of Early Detection Ovarian Cancer Biomarkers (Team Project) 149 0

Closed Protocols

Protocol Name Biomarkers Datasets
Standard Specimen Reference Set: Breast Cancer and Imaging 0 0
Biomarker Detection Using NAPPA Tumor Antigen Arrays 28 0
Breast Reference Set Application: Anu Mathew-Meso Scale (2012) 90 0
EDRN Resource Network Exchange 0 0
PTM Microarray: Request for Year 3 Set-Aside Funds 0 0
Triple Negative Breast Cancer Team Project 77 0
Year 2 Collaborative Project - UCSF and Battelle PNWD 0 0

Publications

Publication Name PubMed ID Journal
Yeast screens identify the RNA polymerase II CTD and SPT5 as relevant targets of BRCA1 interaction. 18197258 PLoS ONE
Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome. 19318476 Clin. Cancer Res.
Inactivation of the MAL gene in breast cancer is a common event that predicts benefit from adjuvant chemotherapy. 19208741 Mol. Cancer Res.
Role of eotaxin-1 signaling in ovarian cancer. 19351767 Clin. Cancer Res.
Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reduction. 21254049 Cancer
Expression signatures of TP53 mutations in serous ovarian cancers. 20504346 BMC Cancer
The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy. 21501600 Biochem. Pharmacol.
Methylation patterns in cell-free plasma DNA reflect removal of the primary tumor and drug treatment of breast cancer patients. 20473856 Int. J. Cancer
Do serum biomarkers really measure breast cancer? 19476629 BMC Cancer
Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care. 19224362 Breast Cancer Res. Treat.
Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer. 16603642 Mol. Cancer Res.
Isogenic normal basal and luminal mammary epithelial isolated by a novel method show a differential response to ionizing radiation. 17409405 Cancer Res.
Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. 15897565 Clin. Cancer Res.
The type III TGF-beta receptor suppresses breast cancer progression. 17160136 J. Clin. Invest.
Pooling of case specimens to create standard serum sets for screening cancer biomarkers. 17301268 Cancer Epidemiol. Biomarkers Prev.
High throughput detection of M6P/IGF2R intronic hypermethylation and LOH in ovarian cancer. 16432260 Nucleic Acids Res.
Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers. 15598772 Cancer Epidemiol. Biomarkers Prev.
Analysis of methylation-sensitive transcriptome identifies GADD45a as a frequently methylated gene in breast cancer. 15735726 Oncogene
Estrogen receptor alpha (ESR1) mutant A908G is not a common feature in benign and malignant proliferations of the breast. 15034868 Genes Chromosomes Cancer
Validation of ovarian cancer gene expression signatures for survival and subtype in formalin fixed paraffin embedded tissues. 23274563 Gynecol. Oncol.
Glutamine synthetase is a genetic determinant of cell type-specific glutamine independence in breast epithelia. 21852960 PLoS Genet.
Evaluation of expression based markers for the detection of breast cancer cells. 16319979 Breast Cancer Res. Treat.
Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. 15082792 Mol. Cell. Biol.
TAFII70 isoform-specific growth suppression correlates with its ability to complex with the GADD45a protein. 15328371 Mol. Cancer Res.
Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer. 18474099 Breast Cancer Res.

To update protocols, publications, biomarkers, or science data, please contact the Informatics Center.

Addresses

Box 3873
Duke University Medical Center

To update addresses, please visit the Data Management and Coordinating Center.

Announcement 7/2/2018

The 33rd EDRN Steering Committee Meeting is from September 5-6, 2018 in Boston, MA. Please click here for meeting registration and hotel information.

The 34th EDRN Steering Committee is from March 18-20, 2019 in Nashville TN.
Announcement 6/1/2018

Dr. Sudhir Srivastava was honored with the 2017 Human Proteome Organization (HUPO) Award for a Distinguished Scientist in Clinical and Translational Proteomics. Please join us in congratulating him on his accomplishments and contributions. The awards were presented at HUPO 2017 in Dublin, Ireland and the winners were present to provide a small talk during the Awards Ceremony and HUPO Lectures.